C S Edeklev1, M Halvorsen1, G Løvland2, S A S Vatnehol2, Ø Gjertsen3, B Nedregaard3, R Sletteberg3, G Ringstad3, P K Eide4,5. 1. From the Department of Neurosurgery (C.S.E., M.H., P.K.E.). 2. Interventional Centre (G.L., S.A.S.V.). 3. Department of Radiology and Nuclear Medicine (Ø.G., B.N. R.S., G.R.), Oslo University Hospital, Rikshospitalet, Oslo, Norway. 4. From the Department of Neurosurgery (C.S.E., M.H., P.K.E.) p.k.eide@medisin.uio.no. 5. Institute of Clinical Medicine (P.K.E.), Faculty of Medicine, University of Oslo, Oslo, Norway.
Abstract
BACKGROUND AND PURPOSE: Intrathecal contrast-enhanced glymphatic MR imaging has shown promise in assessing glymphatic function in patients with dementia. The purpose of this study was to determine the safety profile and feasibility of this new MR imaging technique. MATERIALS AND METHODS: A prospective safety and feasibility study was performed in 100 consecutive patients (58 women and 42 men, 51 ± 19 years of age) undergoing glymphatic MR imaging from September 2015 to August 2018. Short- and long-term serious and nonserious adverse events were registered clinically and by interview after intrathecal administration of 0.5 mL of gadobutrol (1.0 mmol/mL) along with 3 mL of iodixanol (270 mg I/mL). Adverse events are presented as numbers and percentages. RESULTS: One serious adverse event (anaphylaxis) occurred in a patient with known allergy to iodine-containing contrast agents (1%). The main nonserious adverse events during the first 1-3 days after contrast injection included severe headache (28%) and severe nausea (34%), though the frequency depended heavily on the diagnosis. After 4 weeks, adverse events had resolved. CONCLUSIONS: Intrathecal administration of gadobutrol in conjunction with iodixanol for glymphatic MR imaging is safe and feasible. We cannot conclude whether short-duration symptoms such as headache and nausea were caused by gadobutrol, iodixanol, the lumbar puncture, or the diagnosis. The safety profile closely resembles that of iodixanol alone.
BACKGROUND AND PURPOSE: Intrathecal contrast-enhanced glymphatic MR imaging has shown promise in assessing glymphatic function in patients with dementia. The purpose of this study was to determine the safety profile and feasibility of this new MR imaging technique. MATERIALS AND METHODS: A prospective safety and feasibility study was performed in 100 consecutive patients (58 women and 42 men, 51 ± 19 years of age) undergoing glymphatic MR imaging from September 2015 to August 2018. Short- and long-term serious and nonserious adverse events were registered clinically and by interview after intrathecal administration of 0.5 mL of gadobutrol (1.0 mmol/mL) along with 3 mL of iodixanol (270 mg I/mL). Adverse events are presented as numbers and percentages. RESULTS: One serious adverse event (anaphylaxis) occurred in a patient with known allergy to iodine-containing contrast agents (1%). The main nonserious adverse events during the first 1-3 days after contrast injection included severe headache (28%) and severe nausea (34%), though the frequency depended heavily on the diagnosis. After 4 weeks, adverse events had resolved. CONCLUSIONS: Intrathecal administration of gadobutrol in conjunction with iodixanol for glymphatic MR imaging is safe and feasible. We cannot conclude whether short-duration symptoms such as headache and nausea were caused by gadobutrol, iodixanol, the lumbar puncture, or the diagnosis. The safety profile closely resembles that of iodixanol alone.
Authors: Florian Berger; Rahel A Kubik-Huch; Tilo Niemann; Hans Ruedi Schmid; Michael Poetzsch; Johannes M Froehlich; Jürg H Beer; Michael J Thali; Thomas Kraemer Journal: Radiology Date: 2018-05-08 Impact factor: 11.105
Authors: Per Kristian Eide; Lars Magnus Valnes; Erika Kristina Lindstrøm; Kent-Andre Mardal; Geir Ringstad Journal: Fluids Barriers CNS Date: 2021-04-01
Authors: Per Kristian Eide; Aslan Lashkarivand; Åsmund Aleksander Hagen-Kersten; Øivind Gjertsen; Bård Nedregaard; Ruth Sletteberg; Grethe Løvland; Svein Are Sirirud Vatnehol; Are Hugo Pripp; Lars Magnus Valnes; Geir Ringstad Journal: Front Neurol Date: 2022-04-06 Impact factor: 4.086
Authors: Per K Eide; Espen Mariussen; Hilde Uggerud; Are H Pripp; Aslan Lashkarivand; Bjørnar Hassel; Hege Christensen; Markus Herberg Hovd; Geir Ringstad Journal: JCI Insight Date: 2021-05-10